In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Adc Therapeutics SA (NYSE: ADCT) closed the day trading at $3.22 down -2.13% from the previous closing price of $3.29. In other words, the price has decreased by -$2.13 from its previous closing price. On the day, 1.9 million shares were traded. ADCT stock price reached its highest trading level at $3.41 during the session, while it also had its lowest trading level at $3.215.
Ratios:
For a better understanding of ADCT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.34 and its Current Ratio is at 4.63.
Upgrades & Downgrades
In the most recent recommendation for this company, Stephens on November 08, 2024, initiated with a Overweight rating and assigned the stock a target price of $6.
On March 28, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $11.Guggenheim initiated its Buy rating on March 28, 2024, with a $11 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 11 ’24 when Redmile Group, LLC bought 100,000 shares for $3.04 per share. The transaction valued at 304,500 led to the insider holds 15,666,731 shares of the business.
Redmile Group, LLC bought 100,000 shares of ADCT for $304,500 on Dec 11 ’24. The 10% Owner now owns 13,145,712 shares after completing the transaction at $3.04 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADCT now has a Market Capitalization of 398884320 and an Enterprise Value of 630253696. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.30. Its current Enterprise Value per Revenue stands at 8.38 whereas that against EBITDA is -5.187.
Stock Price History:
The Beta on a monthly basis for ADCT is 1.95, which has changed by -0.054597676 over the last 52 weeks, in comparison to a change of 0.13844287 over the same period for the S&P500. Over the past 52 weeks, ADCT has reached a high of $4.80, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is -22.41%, while the 200-Day Moving Average is calculated to be 11.94%.
Shares Statistics:
Over the past 3-months, ADCT traded about 1.10M shares per day on average, while over the past 10 days, ADCT traded about 2136780 shares per day. A total of 112.63M shares are outstanding, with a floating share count of 99.31M. Insiders hold about 19.84% of the company’s shares, while institutions hold 52.66% stake in the company. Shares short for ADCT as of 1763078400 were 5867155 with a Short Ratio of 5.35, compared to 1760486400 on 6374485. Therefore, it implies a Short% of Shares Outstanding of 5867155 and a Short% of Float of 5.72.
Earnings Estimates
Currently, 6.0 analysts are dedicated to thoroughly evaluating and rating the performance of Adc Therapeutics SA (ADCT) in the stock market.The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.26 and low estimates of -$0.29.
Analysts are recommending an EPS of between -$1.34 and -$1.48 for the fiscal current year, implying an average EPS of -$1.41. EPS for the following year is -$1.11, with 6.0 analysts recommending between -$0.84 and -$1.33.
Revenue Estimates
6 analysts predict $18.33M in revenue for. The current quarter. It ranges from a high estimate of $19.3M to a low estimate of $17.48M. As of. The current estimate, Adc Therapeutics SA’s year-ago sales were $16.91MFor the next quarter, 6 analysts are estimating revenue of $19.65M. There is a high estimate of $20.6M for the next quarter, whereas the lowest estimate is $18.7M.
A total of 6 analysts have provided revenue estimates for ADCT’s current fiscal year. The highest revenue estimate was $77.6M, while the lowest revenue estimate was $75.8M, resulting in an average revenue estimate of $76.65M. In the same quarter a year ago, actual revenue was $70.84MBased on 6 analysts’ estimates, the company’s revenue will be $79.61M in the next fiscal year. The high estimate is $92M and the low estimate is $69.2M.
